|Written by Rob Goldman|
After the big stock market reversals on the upside of the past few weeks, we may be at a crossroads again, direction and valuation-wise. I am hopeful that since the S&P 500 Index has risen an average of 1.5% each March for the past 15 years holds true. However, with more attention on the economy, and the fact the U.S. hasn’t grown GDP 3% or higher for the past 10 years (for the first time in nearly a century), it does not bode well. Plus, it just feels like we moved too much too fast.
Still, as we said last week, if you look hard enough, there are bargains to be had. We highlighted a stock in that edition that had a history of crushing EPS and sure enough it did not disappoint as it enjoyed a peak return of 25% by week’s end. Not to be outdone, we have identified another health care stock that has beaten forecasts for 4 straight periods, and carries a dividend yield of over 4%, which could potentially reduce investment risk as well.
IN LIKE A LAMB...
The old saying about the month of March is that the month enters like a lamb and exits like a lion. We all know that refers to the weather, but I contend that we may see the same for the stock market as well.
Don’t get me wrong. I am thrilled that stocks have bounced like they have. Unfortunately, we’ve got some things going against us. For starters, it appears that while valuation may have been a driver of the recent uptick, economic issues may rear their ugly heads again. You know the type...like the one that killed us early in the year…
Let’s face it. If it weren’t for “us consumers”, we’d be up a creek without a paddle. According to a data recently released by the Bureau of Economic Analysis, the U.S. has not generated GDP growth of at least 3% for the past 10 years. To put that in perspective, that is the worst ten year stretch since these figures were tabulated starting after the Crash of ‘29. In fact, we haven't hit the 2.5% mark since 2010. Low growth, very low inflation could chip away at valuations.
Add the drop in Asian currencies and continued poor economic data there and the math does not make me feel warm and fuzzy inside, even though the S&P 500 has aveaged a 1.5% gain in each March since 2000.
The Stock Market Today
If you look at the figures in the table above, you can see that we may have moved too far too fast since the lows achieved less than three weeks ago. After all, stocks have risen an average of over 8% in the past 10 trading sessions. Compared to where we were, that is pretty good. The problem is that we are in no man’s land. With the exception of the Russell 2000 Index, the major indices are pretty much smack dab in the middle of their 52 week high/low ranges. Does that mean stocks are cheap, expensive, or fairly valued?
My answer is that some stocks are cheap, especially in health care and some technology. It is amazing to see how many stocks are actually just above their 52 week lows despite solid earnings growth behind it and expectations ahead. Last week we highlighted LeMaitre Vascular, Inc. (NASDAQ – LMAT - $14.68), a provider of devices and implants for the treatment of peripheral vascular disease, which was a perfect example of these characteristics. Following its mid-week earnings release which blew away Street estimates, the stock peaked with a 25% intra-day performance. This week, we have identified another heath care stock exhibiting EPS outperformance traits, although we expect returns to be more subdued. However, the stock does carry a solid dividend yield which serves to reduce risk to a degree.
Low Valuation, Dividend Paying Small Cap
Select Medical Holdings Corp (NYSE—SEM—$9.67) began operations in 1997 and has grown to be one of the largest operators of specialty hospitals and outpatient rehabilitation clinics in the United States based on number of facilities. Select Medical operates 109 long term acute care hospitals and 18 acute medical rehabilitation hospitals in 28 states, and 1,038 outpatient rehabilitation clinics in 31 states and the D.C. The Company had a very strong 4Q15 and FY15, announced late last week, and is in the process of closing the acquisition of Physiotherapy Associates Holdings, Inc. for $400M in cash which is expected to close in the first half of 2016.
When taking into account this pending deal, Wall Street consensus calls for EPS of $0.89 in 2016 and $1.04 next year. Considering that SEM has beaten EPS expectations by an average of 17% for the past four quarters, it is possible that these numbers could be a tad low. At current levels, SEM trades 10.8x 2016 EPS and also carries a 4.14% annual dividend yield. The stock is 44% off its year high and we believe it could rise by 25% to the $12 level, which assumes a 13.5x P/E.
Great info, insights, and hard-hitting stories make up this week’s Say What? feature...
Breakdown and translation of what The Great One just said...
The New York Post
Reminiscent of the story a few years ago, only now coming to fruition.
The New York Times
A hell of a question.
Nice. All that needs to be said.
Interesting to see, but the forward P/E is what is truly relevant.
1498 Reisterstown Road, Suite 286 Baltimore Maryland 21208 Phone: 410.609.7100
Launched in May 2010, The Goldman Guide is a free weekly publication of Goldman Small Cap Research and is written by Founder Rob Goldman with contributions from the GSCR contributor team. This non-sponsored investment newsletter seeks to provide investors with market, economic, political and equity-specific insights via an action-oriented, straight to the point approach. No companies mentioned in this newsletter are current sponsored research clients of the Company or its parent, unless noted, With some exceptions, all companies or investment ideas mentioned in this publication are publicly traded stocks listed either on the NYSE or the NASDAQ. Goldman Small Cap Research members and contributors’ bios, certifications, and experience can be found on our website: www.goldmanresearch.com
This newsletter was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces non-sponsored and sponsored (paid) investment research. Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The Firm’s non-sponsored research publications category, Select Research, reflects the Firm’s internally generated stock ideas, along with economic, industry and market outlooks. In virtually all cases, stocks mentioned in Select Research offerings are listed on the NYSE or the NASDAQ. Publications in this category include the weekly newsletter The Goldman Guide, Market Monitor blogs, Special Reports, and premium products such as The 30-30 Report. Goldman Small Cap Research analysts are neither long nor short stocks mentioned in this newsletter.
Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in company-specific Opportunity Research reports, updates and articles.
Goldman Small Cap Research has not been compensated for any content in this issue.
All information contained in this newsletter and in our reports were provided by the companies mentioned via news releases, filings, and their websites or generated from our own due diligence. Economic, market data and charts are provided by a variety of sources and are cited upon publication. Stock performance data and information are derived from Yahoo! Finance and other websites or sources, as noted. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, other firms, or other financial news outlets. Goldman Small Cap Research relied solely upon information provided by companies through filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, blog, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
Separate from the factual content of our articles about the company featured in this newsletter, we may from time to time include our own opinions about the companies profiled herein, their businesses, markets and opportunities. Any opinions we may offer about the companies are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.